Evidence map›Paper›PMID 40956095›Full record

ArticlemBio2025

mGem: How many fungal secondary metabolites are produced by filamentous fungi? Conservatively, at least 1.4 million.

Olivia L Riedling, Antonis Rokas

Abstract read
In one paragraph

Article in mBio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Anthracaurisin A─Discovery of a CytotoxicJournal of natural products · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Olivia L RiedlingDepartment of Biological Sciences, Vanderbilt University, Nashville, Tennessee, USA.ORCID 0000-0003-2735-0513
Antonis RokasDepartment of Biological Sciences, Vanderbilt University, Nashville, Tennessee, USA.ORCID 0000-0002-7248-6551

Funding

Deciphering the phenotypic and genomic traits that underlie the evolution of pathogenicity differences among Aspergillus fumigatus and its close relativesR01AI153356 · NIAID · VANDERBILT UNIVERSITY · PI Antonis Rokas · 2022 to 2026
$3.5M
Burroughs Wellcome Fund N/ANational Institute of Allergy and Infectious Diseases R01AI153356National Science Foundation DEB-2110404,2444112NIAID NIH HHS R01 AI153356
6 · The paper itself

Abstract

The ~30,000 known fungal secondary metabolites (SMs) are a vital component of the bioeconomy. SMs are biosynthesized by biosynthetic gene clusters (BGCs), i.e., sets of genes in close physical proximity in the genome. The bulk of these SMs are produced by filamentous fungi in the Pezizomycotina subphylum (phylum Ascomycota). To gauge the magnitude of chemodiversity in this subphylum, we utilized data from the well-characterized genus

Indexed as

AscomycotaBiosynthetic PathwaysFungiSecondary MetabolismAspergillusGenome, FungalMultigene FamilyAspergillusbiosynthetic gene clustersdiversityfunginatural productspezizomycotinasecondary metabolitesspecialized metabolites

Identifiers

PMID40956095
PMCPMC12506122

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.